JessicaJLinMD

Oncology • Boston, MA

Thoracic Cancer

Thoracic Oncologist

Join to view full profile

Dr. Lin is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Connect with other colleagues in the same hospital or clinic
Search all U.S. specialist profiles and refer a patient
Read the latest clinical news and earn CME/CEU credits

See Dr. Lin's full profile

Already have an account?

Office
55 Fruit St
Boston, MA 02114
Phone+1 617-726-2000

Fax+1 617-726-4803
Is this information wrong?

Summary

Dr. Jessica Lin is an oncologist in Boston, MA and is affiliated with Massachusetts General Hospital. She received her medical degree from Harvard Medical School and has been in practice for more than 5 years. She also speaks multiple languages, including Korean. She specializes in thoracic oncology and has expertise in clinical and translational research, early drug development, and clinical trials.

Education & Training

Brigham and Women's Hospital/Massachusetts General Hospital/Dana-Farber Cancer InstituteFellowship, Hematology and Medical Oncology, 2015 - 2018
Brigham and Women's HospitalResidency, Internal Medicine, 2012 - 2015
Harvard Medical SchoolClass of 2012
Harvard UniversityAB

Certifications & Licensure

MA State Medical License 2014 - 2024
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Medical Oncology

Clinical Trials

Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions) Start of enrollment: 2015 Nov 19
Active, not recruiting
Phase 2
A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements Start of enrollment: 2017 Mar 07
Recruiting
Phase 1, Phase 2
Targeted Treatment for ALK Positive Patients Who Have Previously Been Treated for Non-squamous Non-small Cell Lung Cancer Start of enrollment: 2019 Jul 25
Active, not recruiting
Phase 2
Phase Ib Study of TNO155 in Combination With Spartalizumab or Ribociclib in Selected Malignancies Start of enrollment: 2019 Jul 30
Terminated
Phase 1
Study of TPX-0046, A RET/SRC Inhibitor in Adult Subjects With Advanced Solid Tumors Harboring RET Fusions or Mutations Start of enrollment: 2019 Dec 06
Terminated
Phase 1, Phase 2
RLY-1971 in Subjects With Advanced or Metastatic Solid Tumors Start of enrollment: 2020 Feb 04
Completed
Phase 1
Study of Seribantumab in Adult Patients With NRG1 Gene Fusion Positive Advanced Solid Tumors Start of enrollment: 2020 Sep 29
Active, not recruiting
Phase 2
Immune and Genomic Markers in ALK+ NSCLC Start of enrollment: 2021 Dec 01
Recruiting
A Study of NVL-520 in Patients With Advanced NSCLC and Other Solid Tumors Harboring ROS1 Rearrangement (ARROS-1) Start of enrollment: 2022 Jan 04
Recruiting
Phase 1, Phase 2
A Study of TPX-0131, a Novel Oral ALK Tyrosine Kinase Inhibitor, in Patients With ALK+ Advanced or Metastatic NSCLC Start of enrollment: 2021 Jul 28
Terminated
Phase 1
Biology of Young Lung Cancer Study: The YOUNG LUNG Study Start of enrollment: 2023 Jan 01
Recruiting
Roles: Principal Investigator
A Study of NVL-655 in Patients With Advanced NSCLC and Other Solid Tumors Harboring ALK Rearrangement or Activating ALK Mutation (ALKOVE-1) Start of enrollment: 2022 Jun 09
Recruiting
Phase 1, Phase 2
Study Assessing MTD, Safety, Tolerability, PK and Anti-tumor Effects of LNS8801alone and With Pembrolizumab Start of enrollment: 2019 Oct 21
Recruiting
Phase 1, Phase 2
Roles: Contact
Join now to see all

Publications & Presentations

PubMed

Efficacy and Safety of Dose-Escalated Alectinib in Patients With Metastatic ALK-Positive NSCLC and Central Nervous System Relapse on Standard-Dose Alectinib.
Cheung, J., Yeap, B., Peterson, J., Do, A., Kang, J., Gainor, J., Digumarthy, S., Lin, J.> ;JTO Clinical and Research Reports. 2024 Mar 1
Current opportunities and challenges in ALK-positive lung cancer.
Lin, J., Gainor, J.> ;Translational Lung Cancer Research. 2024 Jan 31
Consolidation Osimertinib Versus Durvalumab Versus Observation After Concurrent Chemoradiation in Unresectable EGFR-Mutant NSCLC: A Multicenter Retrospective Cohort St...
D'Aiello, A., Owen, D. H., Amin H Nassar, So Yeon Kim, Jacqueline V Aredo, Jamie Feng, Frances Shepherd, Chao Xu, David Kaldas, Jhanelle E Gray, Thomas J Dilling, Joel...> ;Journal of Thoracic Oncology. 2024 Jan 24
Lorlatinib and capmatinib in a ROS1-rearranged NSCLC with MET-driven resistance: tumor response and evolution.
Jaime L Schneider, Khvaramze Shaverdashvili, Mari Mino-Kenudson, Subba R Digumarthy, Andrew Do, Audrey Liu, Justin F Gainor, Jochen K Lennerz, Timothy F Burns, Jessica...> ;NPJ Precision Oncology. 2023 Nov 3
7 citations
NVL-520 Is a Selective, TRK-Sparing, and Brain-Penetrant Inhibitor of ROS1 Fusions and Secondary Resistance Mutations.
Alexander Drilon, Joshua C Horan, Anupong Tangpeerachaikul, Benjamin Besse, Sai-Hong Ignatius Ou, Shirish M Gadgeel, D Ross Camidge, Anthonie J van der Wekken, Linh Ng...> ;Cancer Discovery. 2023 Mar 1
3 citations
Efficacy and Tolerability of/Combinations in Patients With-Rearranged Lung Cancer With AcquiredAmplification: A Retrospective Analysis.
Ibiayi Dagogo-Jack, Lesli A Kiedrowski, Rebecca S Heist, Jessica J Lin, Catherine B Meador, Elizabeth A Krueger, Andrew Do, Jennifer Peterson, Lecia V Sequist, Justin ...> ;JTO Clinical and Research Reports. 2023 Aug 1
16 citations
Therapy-induced APOBEC3A drives evolution of persistent cancer cells.
Hideko Isozaki, Ramin Sakhtemani, Ammal Abbasi, Naveed Nikpour, Marcello Stanzione, Sunwoo Oh, Adam Langenbucher, Susanna Monroe, Wenjia Su, Heidie Frisco Cabanos, Far...> ;Nature. 2023 Aug 1
12 citations
Clinicopathologic and Genomic Factors Impacting Efficacy of First-Line Chemoimmunotherapy in Advanced NSCLC.
Vaz, V., Joao V Alessi, Arielle Elkrief, Biagio Ricciuti, Xinan Wang, Alessio Cortellini, Victor R Vaz, Giuseppe Lamberti, Rosa L Frias, Deepti Venkatraman, Claudia A ...> ;Journal of Thoracic Oncology. 2023 Jun 1
24 citations
ALK-positive lung cancer: a moving target.
Jaime L Schneider, Jessica J Lin, Alice T Shaw> ;Nature Cancer. 2023 Mar 1
First-line lorlatinib for advanced ALK-positive non-small-cell lung cancer.
Jessica J Lin, Justin F Gainor> ;The Lancet. Respiratory Medicine. 2023 Apr 1
19 citations
Analysis of lorlatinib analogs reveals a roadmap for targeting diverse compound resistance mutations in ALK-positive lung cancer.
Aya Shiba-Ishii, Ted W Johnson, Ibiayi Dagogo-Jack, Mari Mino-Kenudson, Theodore R Johnson, Ping Wei, Scott L Weinrich, Michele A McTigue, Makeba A Walcott, Linh Nguye...> ;Nature Cancer. 2022 Jun 1
120 citations
Third-generation EGFR and ALK inhibitors: mechanisms of resistance and management.
Alissa J Cooper, Lecia V Sequist, Jessica J Lin> ;Nature Reviews. Clinical Oncology. 2022 Aug 1
Response to Provenzano et al. and De Carlo et al.
Or Kalchiem-Dekel, Christine M Bestvina, Justin F Gainor, Alexander Drilon, Jessica J Lin> ;Journal of Thoracic Oncology. 2023 Feb 1
9 citations
Factors Associated With Developing Neurocognitive Adverse Events in Patients Receiving Lorlatinib After Progression on Other Targeted Therapies.
Ibiayi Dagogo-Jack, Antonello Abbattista, Stan Krulewicz, Andrew Do, Jennifer Peterson, Jessica J Lin, Justin F Gainor, Rossella Messina, Elizabeth A Krueger, Holger T...> ;Journal of Thoracic Oncology. 2023 Jan 1
1 citations
Selective Targeting of RET Fusions in Lung Cancer.
Jessica J Lin, Justin F Gainor> ;Journal of Clinical Oncology. 2023 Jan 10
3 citations
Clinicopathologic Characteristics and Outcomes for Patients WithG12D-Mutant NSCLC.
Alona Muzikansky, Jochen Lennerz, Farhaana Narinesingh, Mari Mino-Kenudson, Yin P Hung, Zofia Piotrowska, Ibiayi Dagogo-Jack, Lecia V Sequist, Justin F Gainor, Jessica...> ;JTO Clinical and Research Reports. 2022 Sep 1
2 citations
Author Correction: Third-generation EGFR and ALK inhibitors: mechanisms of resistance and management.
Alissa J Cooper, Lecia V Sequist, Jessica J Lin> ;Nature Reviews. Clinical Oncology. 2022 Nov 1
42 citations
Safety and efficacy of pralsetinib in RET fusion-positive non-small-cell lung cancer including as first-line therapy: update from the ARROW trial.
F Griesinger, G Curigliano, M Thomas, V Subbiah, C S Baik, D S W Tan, D H Lee, D Misch, E Garralda, D-W Kim, A J van der Wekken, J F Gainor, L Paz-Ares, S V Liu, G P K...> ;Annals of Oncology. 2022 Nov 1
14 citations
Brief Report: Chylothorax and Chylous Ascites During RET Tyrosine Kinase Inhibitor Therapy.
Or Kalchiem-Dekel, Christina J Falcon, Christine M Bestvina, Dazhi Liu, Lauren A Kaplanis, Clare Wilhelm, Jordan Eichholz, Guilherme Harada, Lori J Wirth, Subba R Digu...> ;Journal of Thoracic Oncology. 2022 Sep 1
3 citations
A Phase 2 Study of Lorlatinib in Patients With ROS1-Rearranged Lung Cancer With Brain-Only Progression on Crizotinib.
Jaime L Schneider, Alona Muzikansky, Jessica J Lin, Elizabeth A Krueger, Inga T Lennes, Joseph O Jacobson, Michael Cheng, Rebecca S Heist, Zofia Piotrowska, Justin F G...> ;JTO Clinical and Research Reports. 2022 Jul 1
6 citations
LTK fusions: A new target emerges in non-small cell lung cancer.
Alissa J Cooper, Lecia V Sequist, Ted W Johnson, Jessica J Lin> ;Cancer Cell. 2022 Jan 10
23 citations
Efficacy and Safety of Larotrectinib in Patients With Tropomyosin Receptor Kinase Fusion-Positive Lung Cancers.
Alexander Drilon, Daniel S W Tan, Ulrik N Lassen, Serge Leyvraz, Yongmei Liu, Jyoti D Patel, Lee Rosen, Benjamin Solomon, Ricarda Norenberg, Laura Dima, Nicoletta Breg...> ;JCO Precision Oncology. 2022 Jan 1
186 citations
Sequential ALK Inhibitors Can Select for Lorlatinib-Resistant Compound ALK Mutations in ALK-Positive Lung Cancer
Satoshi Yoda, Jessica J. Lin, Michael S. Lawrence, Benjamin J. Burke, Luc Friboulet, Adam Langenbucher, Leila Dardaei, Kylie Prutisto-Chang, Ibiayi Dagogo-Jack, Sergei...> ;Cancer Discovery. 2018 Jan 1
Spectrum of Mechanisms of Resistance to Crizotinib and Lorlatinib in ROS1 Fusion-Positive Lung Cancer.
Lin JJ, Choudhury NJ, Yoda S, Zhu VW, Johnson TW, Sakhtemani R, Dagogo-Jack I, Digumarthy SR, Lee C, Do A, Peterson J, Prutisto-Chang K, Malik W, Hubbeling H, Langenbu...> ;Clinical cancer research : an official journal of the American Association for Cancer Research. 2021-03-08
1 citations
Correction: Updated Integrated Analysis of the Efficacy and Safety of Entrectinib in Patients with NTRK Fusion-Positive Solid Tumors.
Demetri, G., De Braud, F., Drilon, A., Siena, S., Patel, M., Cho, B., Liu, S., Ahn, M., Chiu, C., Lin, J., Goto, K., Lee, J., Bazhenova, L., John, T., Fakih, M., Chawl...> ;Clinical Cancer Research. 2022 May 13
Join now to see all

Books/Book Chapters

IASLC ATLAS OF MOLECULAR TESTING FOR TARGETED THERAPY IN LUNG CANCER
Chapter: RET
Sanja Dajic, Jessica J Lin, Mauro PapottiEdition 2023,
Cancer Chemotherapy, Immunotherapy and Biotherapy
Chapter: Targeted Therapy in Lung Cancer
Hubbeling HG, Lin JJ, Dagogo-Jack I, Gainor JF, Shaw ATEditors: Chabner BA.Wolters Kluwer HealthEdition 6th,

Abstracts/Posters

Safety and preliminary clinical activity of repotrectinib in patients with advanced ROS1 fusion-positive non-small cell lung cancer (TRIDENT-1 study)
Cho BC, Drilon A, Doebele RC, Kim DW, Lin JJ, Lee J, Ahn MJ, Zhu VW, Camidge R, Stopatschinskaja S, Cui JJ, Hyman DM, Ou SI, Shaw AT, ASCO Annual Meeting 2019, Chicago, IL
Efficacy of platinum-pemetrexed combination chemotherapy in ALK+ non-small cell lung cancer refractory to second-generation ALK TKIs
Lin JJ, Schoenfeld AJ, Zhu VW, Yeap BW, Chin E, Rooney M, Plodkowski AJ, Digumarthy SR, Dagogo-Jack I, Gainor JF, Ou SI, Riely GJ, Shaw AT, ASCO Annual Meeting 2019, Chicago, IL
Long-term efficacy and outcomes with sequential crizotinib followed by alectinib in ALK+ NSCLC
Lin JJ, Yeap BY, Ferris LA, Yoda S, Dagogo-Jack I, Lennerz JK, Gainor JF, Shaw AT, ASCO Annual Meeting 2018, Chicago, IL

Lectures

Efficacy of platinum-pemetrexed combination chemotherapy in ALKnon-small cell lung cancer refractory to second-generation ALK TKIs.
ASCO Annual Meeting 2019 - Chicago, IL - 6/2/2019

Press Mentions

Bristol Myers' $4.1B Turning Point buy yields FDA approval for lung cancer drug AugtyroNovember 16th, 2023
FDA Approves Repotrectinib for Locally Advanced or Metastatic ROS1+ NSCLCNovember 15th, 2023
NVL-655 Elicits Preliminary Activity, Safety in Heavily Pretreated, ALK+ Advanced NSCLCOctober 13th, 2023
Join now to see all